Edwards Lifesciences received FDA approval to introduce its SAPIEN 3 Ultra transcatheter aortic heart valve in the U.S. Specifically, the device is indicated for cases of severe, symptomatic aortic stenosis identified to be at intermediate or greater risk of open-heart surgery.
The SAPIEN 3 Ultra has some modifications that make it appropriate to (Read more...)